{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:24:05Z","timestamp":1792801445328,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Shenzhen Scientific Research Program of the People\u2019s Republic of China","award":["No.JCYJ20130402151227180"],"award-info":[{"award-number":["No.JCYJ20130402151227180"]}]},{"name":"Shenzhen Scientific Research Program of the People\u2019s Republic of China","award":["JCYJ20130402151227167"],"award-info":[{"award-number":["JCYJ20130402151227167"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13256-017-1498-6","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T15:26:05Z","timestamp":1511796365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Rhabdomyolysis, lactic acidosis, and multiple organ failure during telbivudine treatment for hepatitis B: a case report and review of the literature"],"prefix":"10.1186","volume":"11","author":[{"given":"Jinxin","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minggui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duoyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"key":"1498_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2893.2010.01274.x","volume":"17","author":"J Sun","year":"2010","unstructured":"Sun J, Hou JL. Management of chronic hepatitis B: experience from China. J Viral Hepat. 2010;17:10\u20137.","journal-title":"J Viral Hepat"},{"key":"1498_CR2","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486\u201395.","journal-title":"Gastroenterology"},{"key":"1498_CR3","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1365-2893.2010.01412.x","volume":"18","author":"XJ Zou","year":"2011","unstructured":"Zou XJ, Jiang XQ, Tian DY. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. J Viral Hepat. 2011;18:892\u20136.","journal-title":"J Viral Hepat"},{"key":"1498_CR4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1743-422X-7-323","volume":"7","author":"J Finsterer","year":"2010","unstructured":"Finsterer J, Ay L. Myotoxicity of telbivudine in pre-existing muscle damage. Virol J. 2010;7:323\u20135.","journal-title":"Virol J"},{"key":"1498_CR5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MAJ.0b013e31821a520e","volume":"342","author":"SS Dang","year":"2011","unstructured":"Dang SS, Gao N, Zhang X, Jia XL. Rhabdomyolysis in a 48-Year-Old Man With Hepatitis B-Induced Cirrhosis. Am J Med Sci. 2011;342:73\u20135.","journal-title":"Am J Med Sci"},{"key":"1498_CR6","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.3748\/wjg.v19.i33.5575","volume":"19","author":"JL Jin","year":"2013","unstructured":"Jin JL, Hu P, Lu JH, et al. Lactic acidosis during telbivudine treatment for HBV: A case report and literature review. World J Gastroenterol. 2013;19:5575\u201380.","journal-title":"World J Gastroenterol"},{"key":"1498_CR7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12325-009-0004-y","volume":"26","author":"K Nash","year":"2009","unstructured":"Nash K. Telbivudine in the treatment of chronic hepatitis B. Adv Ther. 2009;26:155\u201369.","journal-title":"Adv Ther"},{"key":"1498_CR8","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/AAC.46.6.1728-1733.2002","volume":"46","author":"B Hernandez-Santiago","year":"2002","unstructured":"Hernandez-Santiago B, Placidi L, Cretton-Scott E, et al. Pharmacology of beta-L-thymidine and beta-L-2\u2032-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob Agents Chemother. 2002;46:1728\u201333.","journal-title":"Antimicrob Agents Chemother"},{"key":"1498_CR9","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","volume":"357","author":"CL Lai","year":"2007","unstructured":"Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576\u201388.","journal-title":"N Engl J Med"},{"key":"1498_CR10","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.3748\/wjg.v13.i46.6150","volume":"13","author":"DN Amarapurkar","year":"2007","unstructured":"Amarapurkar DN. Telbivudine: a new treatment for chronic hepatitis B. World J Gastroenterol. 2007;13:6150\u20135.","journal-title":"World J Gastroenterol"},{"key":"1498_CR11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jhep.2009.06.011","volume":"51","author":"RD Fleischer","year":"2009","unstructured":"Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol. 2009;51:787\u201391.","journal-title":"J Hepatol"},{"key":"1498_CR12","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.clinthera.2007.12.032","volume":"29","author":"SJ Matthews","year":"2007","unstructured":"Matthews SJ. Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther. 2007;29:2635\u201353.","journal-title":"Clin Ther"},{"key":"1498_CR13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00228-015-1978-9","volume":"72","author":"L Chen","year":"2016","unstructured":"Chen L, Cheng C, Chen BC, Zhao Y, Zhang JM, Wang B. Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine. Eur J Clin Pharmacol. 2016;72:235\u201341.","journal-title":"Eur J Clin Pharmacol"},{"key":"1498_CR14","first-page":"57","volume":"1","author":"B Caroleo","year":"2011","unstructured":"Caroleo B, Galasso O, Staltari O, et al. Muscular damage during telbivudine treatment in a chronic hepatitis B patient. Muscles Ligaments Tendons J. 2011;1:57\u201360.","journal-title":"Muscles Ligaments Tendons J"},{"key":"1498_CR15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s11096-012-9633-3","volume":"34","author":"M Wang","year":"2012","unstructured":"Wang M, Da YW, Cai HD, Lu Y, Wu LY, Jia JP. Telbivudine myopathy in a patient with chronic hepatitis B. Int J Clin Pharm. 2012;34:422\u20135.","journal-title":"Int J Clin Pharm"},{"key":"1498_CR16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3350\/cmh.2013.19.1.82","volume":"19","author":"EH Kim","year":"2013","unstructured":"Kim EH, Park H, Lee KH, Ahn SH, Kim SM, Han KH. Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. Clin Mol Hepatol. 2013;19:82\u20136.","journal-title":"Clin Mol Hepatol"},{"key":"1498_CR17","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/imj.12237","volume":"43","author":"SW Lee","year":"2013","unstructured":"Lee SW, Jang JH, Kim BJ. Dysphagia could be the first presenting symptom of telbivudine-induced myopathy. Intern Med J. 2013;43:1048\u20139.","journal-title":"Intern Med J"},{"key":"1498_CR18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/1751-2980.12173","volume":"16","author":"YH Wang","year":"2015","unstructured":"Wang YH, Wu BQ, Liu H. Continuous venovenous hemodiafiltration for hyperlactatemia caused by telbivudine in a patient with chronic hepatitis B: A case report and update review. J Dig Dis. 2015;16:164\u20137.","journal-title":"J Dig Dis"},{"key":"1498_CR19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/lt.24131","volume":"21","author":"I Turan","year":"2015","unstructured":"Turan I, Yapali S, Bademkiran S, et al. Telbivudine in Liver Transplant Recipients: Renal Protection Does Not Overcome the Risk of Polyneuropathy and Myopathy. Liver Transpl. 2015;21:1066\u201375.","journal-title":"Liver Transpl"},{"key":"1498_CR20","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1002\/hep.22885","volume":"49","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49:S185\u201395.","journal-title":"Hepatology"},{"key":"1498_CR21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/095632020101200205","volume":"12","author":"DN Standring","year":"2001","unstructured":"Standring DN, Bridges EG, Placidi L, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother. 2001;12:119\u201329.","journal-title":"Antivir Chem Chemother"},{"key":"1498_CR22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jns.2015.08.1550","volume":"358","author":"A Hern\u00e1ndez-La\u00edn","year":"2015","unstructured":"Hern\u00e1ndez-La\u00edn A, Guerrero AM, Dom\u00ednguez-Gonz\u00e1lez C, et al. A novel RRM2B gene variant associated with Telbivudine-induced mitochondrial myopathy. J Neurol Sci. 2015;358:481\u20133.","journal-title":"J Neurol Sci"},{"key":"1498_CR23","first-page":"557","volume":"38","author":"SD Register","year":"2011","unstructured":"Register SD, Aaron ME, Gelly HB. Hyperbaric oxygen therapy and optic neuritis: case report and literature review. Undersea Hyperb Med. 2011;38:557\u20139.","journal-title":"Undersea Hyperb Med"},{"key":"1498_CR24","first-page":"1111","volume":"39","author":"M Pell","year":"2012","unstructured":"Pell M, Saththasivam P, Stephens PL, Mychaskiw 2nd G. Therapeutic effect of hyperbaric oxygen on inclusion body myositis. Undersea Hyperb Med. 2012;39:1111\u20134.","journal-title":"Undersea Hyperb Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-017-1498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T15:26:11Z","timestamp":1511796371000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-017-1498-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,27]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1498"],"URL":"https:\/\/doi.org\/10.1186\/s13256-017-1498-6","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,27]]},"article-number":"331"}}